DOI 10.1016/j.trsl.2026.02.007
Exploring high-affinity MAGE-A3-specific T-cell receptors derived from healthy donor PBMCs: A preclinical evaluation.
Аннотация
BACKGROUND
T cell receptor (TCR) therapy is a promising immunotherapy for cancers, leveraging tumor-associated antigens (TAAs) for targeted treatment. MAGE-A3, a cancer-testis antigen, is highly expressed in multiple malignancies, making it an attractive target. However, efficient identification of high-affinity, tumor-specific TCRs remains a challenge.
METHODS
Healthy donor peripheral blood mononuclear cells (PBMCs) were stimulated ex vivo with multi-epitope mRNA or peptide pools to isolate MAGE-A3-specific TCRs. Functional assays, in vivo xenograft models, and structural modeling were used to evaluate TCR efficacy, specificity, and safety.
RESULTS
Seven MAGE-A3-specific TCRs were identified, with G0507 showing the highest clinical potential. G0507 TCR-T cells demonstrated robust cytotoxicity against MAGE-A3-expressing tumor cells, minimal cross-reactivity, and significant tumor growth inhibition in xenograft models without toxicity. Structural modeling revealed key residues critical for TCR-pMHC interaction, aiding epitope selection and TCR optimization.
CONCLUSIONS
This study demonstrates the feasibility of deriving functional TCRs from healthy donors and highlights the importance of epitope selection for advancing TCR-based therapies. G0507 represents a promising candidate for clinical development, providing a foundation for future cancer immunotherapy strategies targeting MAGE-A3.
Предметные рубрики MeSH
Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.